Crispr Therapeutics AG’s stock CRSP, +0.49% rallied 17% in premarket trade Wednesday, after a positive meeting of a . Food and Drug Administration advisory panel on the gene-editing drug exa-cel developed by Crispr and partner Vertex Pharmaceuticals VRTX, +1.30% as a treatment for sickle-cell disease. The FDA has set a Dec. 8 target action date for possible approval of the treatment, which would be the first approved therapy that uses the gene-editing technology called Crispr.
“Rational thinking prevailed at today’s FDA ad com,” wrote analysts at Evercore ISI, in a note. “We think exa-cel is very likely to be approved by December 8.”The analysts described it as a “clearing event” for Vertex and a “nice win for CRSP, their platform, and important medical advancement for the field and for patients.” Sickle-cell disease is a painful inherited blood disorder that affects an estimated 70,000 to 100,000 Americans a year, according to the American Society of Hematology.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: MarketWatch - 🏆 3. / 97 Read more »
Source: MarketWatch - 🏆 3. / 97 Read more »
Source: ReutersScience - 🏆 559. / 51 Read more »
Source: physorg_com - 🏆 388. / 55 Read more »